CA2877434A1 - Method of treating lymphoma using thienotriazolodiazepine compounds - Google Patents

Method of treating lymphoma using thienotriazolodiazepine compounds Download PDF

Info

Publication number
CA2877434A1
CA2877434A1 CA2877434A CA2877434A CA2877434A1 CA 2877434 A1 CA2877434 A1 CA 2877434A1 CA 2877434 A CA2877434 A CA 2877434A CA 2877434 A CA2877434 A CA 2877434A CA 2877434 A1 CA2877434 A1 CA 2877434A1
Authority
CA
Canada
Prior art keywords
cell
carbon number
lymphoma
formula
alkyl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
CA2877434A
Other languages
English (en)
French (fr)
Inventor
Francesco Bertoni
Paola BONETTI
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Oncoethix GmbH
Original Assignee
Oncoethix GmbH
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Oncoethix GmbH filed Critical Oncoethix GmbH
Publication of CA2877434A1 publication Critical patent/CA2877434A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A61K31/551—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having two nitrogen atoms, e.g. dilazep
    • A61K31/5513—1,4-Benzodiazepines, e.g. diazepam or clozapine
    • A61K31/5517—1,4-Benzodiazepines, e.g. diazepam or clozapine condensed with five-membered rings having nitrogen as a ring hetero atom, e.g. imidazobenzodiazepines, triazolam
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A61K31/551—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having two nitrogen atoms, e.g. dilazep
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Hematology (AREA)
  • Oncology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
CA2877434A 2012-06-25 2013-06-25 Method of treating lymphoma using thienotriazolodiazepine compounds Abandoned CA2877434A1 (en)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201261663885P 2012-06-25 2012-06-25
US61/663,885 2012-06-25
US201261670918P 2012-07-12 2012-07-12
US61/670,918 2012-07-12
PCT/EP2013/063313 WO2014001356A1 (en) 2012-06-25 2013-06-25 Method of treating lymphoma using thienotriazolodiazepine compounds

Publications (1)

Publication Number Publication Date
CA2877434A1 true CA2877434A1 (en) 2014-01-03

Family

ID=48672651

Family Applications (1)

Application Number Title Priority Date Filing Date
CA2877434A Abandoned CA2877434A1 (en) 2012-06-25 2013-06-25 Method of treating lymphoma using thienotriazolodiazepine compounds

Country Status (12)

Country Link
US (1) US20140018353A1 (enExample)
EP (1) EP2863923B1 (enExample)
JP (1) JP6265979B2 (enExample)
KR (1) KR20150045423A (enExample)
CN (1) CN105050605A (enExample)
AU (1) AU2013283378B2 (enExample)
BR (1) BR112014032105A2 (enExample)
CA (1) CA2877434A1 (enExample)
IN (1) IN2014DN11269A (enExample)
MX (1) MX2014015986A (enExample)
RU (1) RU2659171C2 (enExample)
WO (1) WO2014001356A1 (enExample)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN108070562A (zh) * 2018-02-03 2018-05-25 金华市中心医院 一种“双打击”弥漫大b细胞淋巴瘤细胞系制备方法

Families Citing this family (34)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2015508414A (ja) 2012-01-12 2015-03-19 イエール ユニバーシティ Ｅ３ユビキチンリガーゼによる標的タンパク質および他のポリペプチドの分解増強のための化合物および方法
US9227985B2 (en) 2013-03-15 2016-01-05 Incyte Corporation Tricyclic heterocycles as bet protein inhibitors
EP3019502B1 (en) 2013-07-08 2017-05-17 Incyte Holdings Corporation Tricyclic heterocycles as bet protein inhibitors
CN106029077A (zh) * 2013-08-01 2016-10-12 翁科埃斯克斯有限公司 包含噻吩并三唑并二氮杂卓化合物的药物制剂
WO2015018522A1 (en) * 2013-08-06 2015-02-12 Oncoethix Sa Bet-bromodomain inhibitor shows synergism with several anti-cancer agents in pre-clinical models of diffuse large b-cell lymphoma (dlbcl)
WO2015018520A1 (en) * 2013-08-06 2015-02-12 Oncoethix Sa A bet-brd inhibitor represents a novel agent for alk positive anaplastic large cell lymphoma
KR20160037201A (ko) * 2013-08-06 2016-04-05 온코에틱스 게엠베하 Bet-브로모도메인 억제제를 사용한 미만성 거대 b-세포 림프종 (dlbcl)의 치료 방법
WO2015081189A1 (en) 2013-11-26 2015-06-04 Incyte Corporation Bicyclic heterocycles as bet protein inhibitors
US9399640B2 (en) 2013-11-26 2016-07-26 Incyte Corporation Substituted pyrrolo[2,3-c]pyridines and pyrazolo[3,4-c]pyridines as BET protein inhibitors
CN105960239A (zh) 2013-11-27 2016-09-21 翁科埃斯克斯有限公司 利用含有噻吩并三唑并二氮杂*化合物的药物制剂治疗白血病的方法
US9309246B2 (en) 2013-12-19 2016-04-12 Incyte Corporation Tricyclic heterocycles as BET protein inhibitors
US20180228907A1 (en) 2014-04-14 2018-08-16 Arvinas, Inc. Cereblon ligands and bifunctional compounds comprising the same
MY180775A (en) 2014-04-23 2020-12-09 Incyte Corp 1h-pyrrolo[2,3-c]pyridin-7(6h)-ones and pyrazolo[3,4-c]pyridin-7(6h)-ones as inhibitors of bet proteins
EP3137086A4 (en) * 2014-05-02 2017-12-27 Oncoethix GmbH Method of treating resistant non-hodgkin lymphoma, medulloblastoma, and/or alk+non-small cell lung cancer using thienotriazolodiazepine compounds
KR20160145833A (ko) 2014-05-02 2016-12-20 온코에틱스 게엠베하 티에노트리아졸로디아제핀 화합물을 사용한 급성 골수성 백혈병 및/또는 급성 림프아구성 백혈병의 치료 방법
BR112016026046A8 (pt) 2014-05-08 2021-07-20 Oncoethix Gmbh uso de compostos de tienotriazolodiazepina
JP2017517579A (ja) 2014-06-13 2017-06-29 オンコエシックス ゲーエムベーハー チエノトリアゾロジアゼピン化合物を用いる非小細胞肺癌及び／又は小細胞肺癌の治療方法
EP3182976A1 (en) 2014-08-19 2017-06-28 Oncoethix GmbH Methods of treating lymphoma using thienotriazolodiazepine compounds
US9527864B2 (en) 2014-09-15 2016-12-27 Incyte Corporation Tricyclic heterocycles as BET protein inhibitors
KR101675984B1 (ko) * 2015-02-23 2016-11-14 한양대학교 에리카산학협력단 티에노디아제핀 유도체 또는 이의 약학적으로 허용가능한 염, 및 이를 유효성분으로 포함하는 약학적 조성물
JP7269731B2 (ja) 2015-03-18 2023-05-09 アルビナス・オペレーションズ・インコーポレイテッド 標的タンパク質の分解向上のための化合物および方法
US10683305B2 (en) 2015-04-27 2020-06-16 Concert Pharmaceuticals, Inc. Deuterated OTX-015
CN108137507A (zh) 2015-07-10 2018-06-08 阿尔维纳斯股份有限公司 基于mdm2的蛋白水解调节剂和相关的使用方法
EP3337476A4 (en) 2015-08-19 2019-09-04 Arvinas, Inc. Compounds and methods for the targeted degradation of bromodomain-containing proteins
WO2017075377A1 (en) 2015-10-29 2017-05-04 Incyte Corporation Amorphous solid form of a bet protein inhibitor
US20170281784A1 (en) 2016-04-05 2017-10-05 Arvinas, Inc. Protein-protein interaction inducing technology
KR102643344B1 (ko) 2016-06-20 2024-03-07 인사이트 코포레이션 Bet 저해제의 결정질 고체 형태
EP3577109A4 (en) 2017-01-31 2020-11-18 Arvinas Operations, Inc. CEREMONY LIGANDS AND BIFUNCTIONAL COMPOUNDS CONTAINING THEM
JP2021512153A (ja) 2018-01-26 2021-05-13 イエール ユニバーシティ タンパク質分解のイミド系モジュレーターおよび使用方法
EP3774772A1 (en) 2018-04-13 2021-02-17 Arvinas Operations, Inc. Cereblon ligands and bifunctional compounds comprising the same
EP3849987B1 (en) 2018-09-11 2024-04-17 F. Hoffmann-La Roche AG Tert-butyl (s)-2-(4-(phenyl)-6h-thieno[3,2-f][1,2,4]triazolo[4,3-a] [1,4]diazepin-6-yl) acetate derivatives and related compounds as bromodomain brd4 inhibitors for treating cancer
EP4077309A1 (en) 2019-12-19 2022-10-26 Arvinas Operations, Inc. Compounds and methods for the targeted degradation of androgen receptor
US11833155B2 (en) 2020-06-03 2023-12-05 Incyte Corporation Combination therapy for treatment of myeloproliferative neoplasms
WO2025049555A1 (en) 2023-08-31 2025-03-06 Oerth Bio Llc Compositions and methods for targeted inhibition and degradation of proteins in an insect cell

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1994006802A1 (fr) 1992-09-18 1994-03-31 Yoshitomi Pharmaceutical Industries, Ltd. Compose de thienodiazepine et son utilisation medicinale
DE69717160T2 (de) * 1996-09-13 2003-05-08 Mitsubishi Pharma Corp., Osaka Thienotriazolodiazepinverbindungen und ihre medizinischen anwendungen
US8476260B2 (en) * 2007-12-28 2013-07-02 Mitsubishi Tanabe Pharma Corporation Antitumor agent
MX384074B (es) * 2010-05-14 2025-03-12 Dana Farber Cancer Inst Inc Composiciones y métodos para tratar neoplasias, enfermedades inflamatorias y otros trastornos.
JP5715241B2 (ja) * 2010-05-14 2015-05-07 ダナ−ファーバー キャンサー インスティテュート， インコーポレイテッド 新生物、炎症性疾患、およびその他の障害を治療するための組成物および方法
WO2013033420A1 (en) * 2011-08-30 2013-03-07 Whitehead Institute For Biomedical Research Methods of downregulating translocated oncogene expression using bromodomain inhibitors

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN108070562A (zh) * 2018-02-03 2018-05-25 金华市中心医院 一种“双打击”弥漫大b细胞淋巴瘤细胞系制备方法

Also Published As

Publication number Publication date
JP6265979B2 (ja) 2018-01-24
AU2013283378A1 (en) 2015-01-29
EP2863923A1 (en) 2015-04-29
RU2015101106A (ru) 2016-08-10
KR20150045423A (ko) 2015-04-28
WO2014001356A1 (en) 2014-01-03
EP2863923B1 (en) 2019-05-08
RU2659171C2 (ru) 2018-06-28
JP2015531747A (ja) 2015-11-05
BR112014032105A2 (pt) 2017-08-01
IN2014DN11269A (enExample) 2015-10-09
MX2014015986A (es) 2016-02-11
CN105050605A (zh) 2015-11-11
US20140018353A1 (en) 2014-01-16
AU2013283378B2 (en) 2017-07-13

Similar Documents

Publication Publication Date Title
AU2013283378B2 (en) Method of treating lymphoma using thienotriazolodiazepine compounds
D’Amore et al. Role of CK2 inhibitor CX-4945 in anti-cancer combination therapy–potential clinical relevance
US20230070600A1 (en) Combination Therapy for Treating or Preventing Depression or Other Mood Diseases
Huang et al. Honokiol inhibits in vitro and in vivo growth of oral squamous cell carcinoma through induction of apoptosis, cell cycle arrest and autophagy
Lee et al. An effective strategy for increasing the radiosensitivity of Human lung Cancer cells by blocking Nrf2-dependent antioxidant responses
Liu et al. Mefloquine effectively targets gastric cancer cells through phosphatase-dependent inhibition of PI3K/Akt/mTOR signaling pathway
Lin et al. Zoledronic acid induces autophagic cell death in human prostate cancer cells
Zhuo et al. Combination therapy with taurine, epigallocatechin gallate and genistein for protection against hepatic fibrosis induced by alcohol in rats
EP3484477B1 (en) Treatment of cancer
RU2013131241A (ru) Композиции, содержащие ингибитор рi3к и ингибитор мек, а также их применение для лечения рака
Ren et al. Blockade efficacy of MEK/ERK-dependent autophagy enhances PI3K/Akt inhibitor NVP-BKM120's therapeutic effectiveness in lung cancer cells
AU2019261718A1 (en) Cancer treatment
AU2011234644A1 (en) PKC inhibitors for the treatment of B-cell lymphoma having chronic active B-cell-receptor signalling
Shahrokhi Nejad et al. The role of AMPK in pancreatic cancer: from carcinogenesis to treatment
Zhang et al. Bioevaluation of a dual PI3K/HDAC inhibitor for the treatment of diffuse large B-cell lymphoma
Kawahara et al. Caffeine dose-dependently potentiates the antitumor effect of cisplatin on osteosarcomas
Wu et al. Inhibition of cyclooxygenase-1 lowers proliferation and induces macroautophagy in colon cancer cells
Zuo et al. BRD4 inhibition sensitizes aggressive non-Hodgkin lymphomas to PI3Kδ inhibitors by suppressing PI3K reactivation and c-MYC expression
Zuo et al. Inhibition of Bromodomain-Containing 4 Sensitises Aggressive Non-Hodgkin Lymphomas to Phosphatidylinositol 3-Kinase δ Inhibitors
WO2008116163A1 (en) Therapeutic drug combinations for treatment of b-cell malignancies
Zhang et al. Phosphatidylinositol-3-kinase/Protein Kinase B Signaling Pathway: A Pivotal Factor for Stimulating Multidrug Resistance in Hepatocellular Carcinoma Cells
Zhou Determination the Role of Constitutive Nitric Oxide Synthase in Skin Carcinogenesis Post UV Irradiation
Morgan et al. 193 Effects of combining amuvatinib (MP-470) with DNA-damaging agents in osteosarcoma cell lines
Shen et al. Open Journal of Pharmacology
Monteiro mTor and Ercci-Immunohistochemistry Expression in Small Cell Lung Carcinoma

Legal Events

Date Code Title Description
EEER Examination request

Effective date: 20160111

FZDE Discontinued

Effective date: 20190228